DK332888A - FACTOR VIII: C-DERIVATIVE, ITS MANUFACTURING AND USE - Google Patents

FACTOR VIII: C-DERIVATIVE, ITS MANUFACTURING AND USE

Info

Publication number
DK332888A
DK332888A DK332888A DK332888A DK332888A DK 332888 A DK332888 A DK 332888A DK 332888 A DK332888 A DK 332888A DK 332888 A DK332888 A DK 332888A DK 332888 A DK332888 A DK 332888A
Authority
DK
Denmark
Prior art keywords
derivative
manufacturing
factor viii
viii
factor
Prior art date
Application number
DK332888A
Other languages
Danish (da)
Other versions
DK332888D0 (en
Inventor
Klaus-Dieter Langner
Egon Amann
Hans Kuepper
Gerd Zettlmeissl
Bernard Huber
Original Assignee
Behringwerke Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Behringwerke Ag filed Critical Behringwerke Ag
Publication of DK332888D0 publication Critical patent/DK332888D0/en
Publication of DK332888A publication Critical patent/DK332888A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DK332888A 1987-06-19 1988-06-17 FACTOR VIII: C-DERIVATIVE, ITS MANUFACTURING AND USE DK332888A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19873720246 DE3720246A1 (en) 1987-06-19 1987-06-19 FACTOR VIII: C-LIKE MOLECULE WITH COAGULATION ACTIVITY

Publications (2)

Publication Number Publication Date
DK332888D0 DK332888D0 (en) 1988-06-17
DK332888A true DK332888A (en) 1988-12-20

Family

ID=6329877

Family Applications (1)

Application Number Title Priority Date Filing Date
DK332888A DK332888A (en) 1987-06-19 1988-06-17 FACTOR VIII: C-DERIVATIVE, ITS MANUFACTURING AND USE

Country Status (8)

Country Link
EP (1) EP0295597A3 (en)
JP (1) JPS6425799A (en)
KR (1) KR890000666A (en)
AU (1) AU609829B2 (en)
DE (1) DE3720246A1 (en)
DK (1) DK332888A (en)
FI (1) FI882890A (en)
PT (1) PT87752B (en)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5661008A (en) * 1991-03-15 1997-08-26 Kabi Pharmacia Ab Recombinant human factor VIII derivatives
SE468050C (en) * 1991-03-15 1998-04-27 Pharmacia & Upjohn Ab Recombinant human factor VIII derivative
AU6456096A (en) * 1995-07-11 1997-02-10 Chiron Corporation Lysine 1689 factor viii:c polypeptide analogs
US8183344B2 (en) 1996-04-24 2012-05-22 University Of Michigan Inactivation resistant factor VIII
EP1754718B1 (en) 1996-04-24 2011-03-23 The Regents Of The University Of Michigan Inactivation resistant factor VIII
EP1038959A1 (en) 1999-03-17 2000-09-27 Aventis Behring Gesellschaft mit beschränkter Haftung Factor VIII without B-domain, comprising one or more insertions of a truncated intron I of factor IX
EP1233064A1 (en) 2001-02-09 2002-08-21 Aventis Behring Gesellschaft mit beschränkter Haftung Modified factor VIII cDNA and its use for the production of factor VIII
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
US7855279B2 (en) 2005-09-27 2010-12-21 Amunix Operating, Inc. Unstructured recombinant polymers and uses thereof
WO2010091122A1 (en) 2009-02-03 2010-08-12 Amunix, Inc. Extended recombinant polypeptides and compositions comprising same
US20120263701A1 (en) 2009-08-24 2012-10-18 Volker Schellenberger Coagulation factor vii compositions and methods of making and using same
ES2717902T5 (en) 2009-10-02 2022-11-29 Childrens Hospital Philadelphia Compositions and methods for improving the function of coagulation factor VIII
HUE036233T2 (en) 2009-12-06 2018-06-28 Bioverativ Therapeutics Inc Factor viii-fc chimeric and hybrid polypeptides, and methods of use thereof
EP3508573A1 (en) 2010-07-09 2019-07-10 Bioverativ Therapeutics Inc. Systems for factor viii processing and methods thereof
KR20140002601A (en) 2010-07-09 2014-01-08 바이오겐 이데크 헤모필리아 인코포레이티드 Chimeric clotting factors
EP3527218A1 (en) 2011-06-10 2019-08-21 Bioverativ Therapeutics Inc. Pro-coagulant compounds and methods of use thereof
EP4169525A1 (en) 2011-07-08 2023-04-26 Bioverativ Therapeutics Inc. Factor viii chimeric and hybrid polypeptides, and methods of use thereof
US10656167B2 (en) 2011-07-25 2020-05-19 Bioverativ Therapeutics Inc. Assays to monitor bleeding disorders
CA2850579A1 (en) 2011-10-18 2013-04-25 Carsten Horn Method for improving the stability of purified factor viii after reconstitution
EA029560B1 (en) 2012-01-12 2018-04-30 Байоджен Эмэй Инк. Use of chimeric blood coagulation factor for reducing inhibitory immune response in a subject
CN104271150A (en) 2012-01-12 2015-01-07 比奥根艾迪克Ma公司 Chimeric factor viii polypeptides and uses thereof
EP2822577B1 (en) 2012-02-15 2019-02-06 Bioverativ Therapeutics Inc. Recombinant factor viii proteins
LT2814840T (en) 2012-02-15 2020-02-25 Bioverativ Therapeutics Inc. Factor viii compositions and methods of making and using same
EP4079316A1 (en) 2012-06-08 2022-10-26 Bioverativ Therapeutics Inc. Procoagulant compounds
WO2013185114A2 (en) 2012-06-08 2013-12-12 Biogen Idec Ma Inc. Chimeric clotting factors
EP3404105A1 (en) 2012-07-06 2018-11-21 Bioverativ Therapeutics Inc. Cell line expressing single chain factor viii polypeptides and uses thereof
PT2882450T (en) 2012-07-11 2020-02-19 Bioverativ Therapeutics Inc Factor viii complex with xten and von willebrand factor protein, and uses thereof
US10001495B2 (en) 2012-07-25 2018-06-19 Bioverativ Therapeutics Inc. Blood factor monitoring assay and uses thereof
EP2908847B1 (en) 2012-10-18 2022-03-30 Bioverativ Therapeutics Inc. Methods of using a fixed dose of a clotting factor
EP2914293A4 (en) 2012-10-30 2016-04-20 Biogen Ma Inc Methods of using fviii polypeptide
DK3889173T3 (en) 2013-02-15 2023-10-09 Bioverativ Therapeutics Inc OPTIMIZED FACTOR VIII GENE
JP6330026B2 (en) 2013-03-15 2018-05-23 バイオベラティブ セラピューティクス インコーポレイテッド Factor VIII polypeptide preparation
MX2015016567A (en) 2013-06-28 2016-03-31 Biogen Ma Inc Thrombin cleavable linker with xten and its uses thereof.
EP3043813B1 (en) 2013-08-08 2021-01-13 Bioverativ Therapeutics Inc. Purification of chimeric fviii molecules
EP3033097B1 (en) 2013-08-14 2021-03-10 Bioverativ Therapeutics Inc. Factor viii-xten fusions and uses thereof
WO2015070014A1 (en) 2013-11-08 2015-05-14 Biogen Idec Ma Inc. Procoagulant fusion compound
US10325687B2 (en) 2013-12-06 2019-06-18 Bioverativ Therapeutics Inc. Population pharmacokinetics tools and uses thereof
DK4176894T3 (en) 2014-01-10 2024-05-27 Bioverativ Therapeutics Inc CHIMERIC FACTOR VIII PROTEINS AND USES THEREOF
KR20230136616A (en) 2014-02-04 2023-09-26 바이오젠 엠에이 인코포레이티드 Use of cation-exchange chromatography in the flow-through mode to enrich post-translational modifications
MA40864A (en) 2014-10-31 2017-09-05 Biogen Ma Inc HYPOTAURINE, GABA, BETA-ALANINE AND CHOLINE FOR THE REGULATION OF THE ACCUMULATION OF RESIDUAL BY-PRODUCTS IN MAMMAL CELL CULTURE PROCESSES
AU2016301303B2 (en) 2015-08-03 2021-10-07 Bioverativ Therapeutics Inc. Factor IX fusion proteins and methods of making and using same
PT3411478T (en) 2016-02-01 2022-09-13 Bioverativ Therapeutics Inc Optimized factor viii genes
EP3548066A1 (en) 2016-12-02 2019-10-09 Bioverativ Therapeutics Inc. Methods of treating hemophilic arthropathy using chimeric clotting factors
BR112019011198A2 (en) 2016-12-02 2019-12-17 Bioverativ Therapeutics Inc methods of inducing immune tolerance to coagulation factors
SG11202000764RA (en) 2017-08-09 2020-02-27 Bioverativ Therapeutics Inc Nucleic acid molecules and uses thereof
MX2020003351A (en) 2017-09-27 2020-10-12 Sigilon Therapeutics Inc Methods, compositions, and implantable elements comprising active cells.
BR112020015228A2 (en) 2018-02-01 2020-12-29 Bioverativ Therapeutics Inc. USE OF LENTIVIRAL VECTORS THAT EXPRESS FACTOR VIII
US20210145889A1 (en) 2018-04-04 2021-05-20 Sigilon Therapeutics, Inc. Methods, compositions, and implantable elements comprising stem cells
TW202014181A (en) 2018-04-04 2020-04-16 美商希吉隆醫療公司 Implantable particles and related methods
AU2019270184A1 (en) 2018-05-18 2020-11-26 Bioverativ Therapeutics Inc. Methods of treating hemophilia A
MX2021001599A (en) 2018-08-09 2021-07-02 Bioverativ Therapeutics Inc Nucleic acid molecules and uses thereof for non-viral gene therapy.
UY38389A (en) 2018-09-27 2020-04-30 Sigilon Therapeutics Inc IMPLANTABLE DEVICES FOR CELLULAR THERAPY AND RELATED METHODS
EP3986444A1 (en) 2019-06-19 2022-04-27 Bioverativ Therapeutics Inc. Recombinant factor viii-fc for treating hemophilia and low bone mineral density
AU2022332276A1 (en) 2021-08-23 2024-04-04 Bioverativ Therapeutics Inc. Optimized factor viii genes
WO2023056331A1 (en) 2021-09-30 2023-04-06 Bioverativ Therapeutics Inc. Nucleic acids encoding factor viii polypeptides with reduced immunogenicity
WO2024081310A1 (en) 2022-10-11 2024-04-18 Sigilon Therapeutics, Inc. Engineered cells and implantable elements for treatment of disease
WO2024081309A1 (en) 2022-10-11 2024-04-18 Sigilon Therapeutics, Inc. Engineered cells and implantable elements for treatment of disease

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR910006424B1 (en) * 1985-08-21 1991-08-24 인코텍스 비.브이 Method of manufacturing knitted briefs
US5451521A (en) * 1986-05-29 1995-09-19 Genetics Institute, Inc. Procoagulant proteins
IL83192A (en) * 1986-07-18 1992-11-15 Gist Brocades Nv Method for the preparation of proteins with factor viii activity by microbial host cells;expression vectors,host cells,antibodies
AU606925B2 (en) * 1987-01-30 1991-02-21 Biogen, Inc. A method for producing factor viii in high yield
EP0690126B1 (en) * 1987-06-12 2001-11-28 Baxter Aktiengesellschaft Novel proteins with factor VIII activitiy: process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them

Also Published As

Publication number Publication date
JPS6425799A (en) 1989-01-27
PT87752B (en) 1992-10-30
AU1810388A (en) 1988-12-22
EP0295597A2 (en) 1988-12-21
FI882890A0 (en) 1988-06-16
DE3720246A1 (en) 1988-12-29
EP0295597A3 (en) 1990-05-02
PT87752A (en) 1988-07-01
FI882890A (en) 1988-12-20
DK332888D0 (en) 1988-06-17
AU609829B2 (en) 1991-05-09
KR890000666A (en) 1989-03-16

Similar Documents

Publication Publication Date Title
DK332888D0 (en) FACTOR VIII: C-DERIVATIVE, ITS MANUFACTURING AND USE
DK656189A (en) STABILIZED SUCRALOS COMPLEX, ITS MANUFACTURING AND USE
DK223388A (en) SUBSTRATE, ITS MANUFACTURING AND USE
DK537089D0 (en) SYNERGISTIC SWEATER, ITS MANUFACTURING AND USE
NO851563L (en) FUNCTIONAL, HUMAN FACTOR VIII AND PROCEDURES FOR PRODUCING THEREOF.
DK609689A (en) FOLIAMINATE AND ITS USE
DK555586D0 (en) HARDENING PRODUCT, ITS MANUFACTURING AND USE
NO882385L (en) POLYPEPTIME AND PRODUCTION THEREOF.
DK285388A (en) PEPTIME AND ITS USE
NO891334L (en) SUPERLY MATERIAL AND PROCEDURE FOR ITS MANUFACTURING.
DK87487A (en) FUNGICID AGENT, ITS MANUFACTURING AND USE
DK668988D0 (en) MONOAZOPIGMENTS, THEIR MANUFACTURING AND USE
DK388489D0 (en) SYNERGISTIC SWEATER, ITS MANUFACTURING AND USE
DK525687D0 (en) ENZYMOUS PREPARATION, ITS MANUFACTURING AND USE
DK408688D0 (en) AUTODESINFINING PRINT MATERIAL, ITS MANUFACTURING AND USE
NO881902D0 (en) SOPPAROMA AND MANUFACTURING THEREOF.
NO884120D0 (en) SUPERVISIVE MATERIAL AND PROCEDURE FOR ITS MANUFACTURING.
DK125087A (en) EFOMYCIN G., ITS MANUFACTURING AND USE
DK285288D0 (en) PEPTIME AND ITS USE
DK144084A (en) MAKROLID, ITS MANUFACTURING AND USE
DK587588D0 (en) POLYPEPTID, ITS USE AND MANUFACTURING
DK587688D0 (en) POLYPEPTID, ITS USE AND MANUFACTURING
DK690587D0 (en) TETRAPEPTIME, ITS MANUFACTURING AND USE
DK545287A (en) HYBRID PLASMID ITS MANUFACTURING AND USE
DK294987D0 (en) PLASMID, CALLED PADE161, ITS MANUFACTURING AND USE

Legal Events

Date Code Title Description
ATS Application withdrawn